Nycomed was in turn acquired by Takeda in 2011 and Wyeth was acquired by Pfizer in 2009.The patent protecting the drug was set to expire in 2010, but Teva Pharmaceuticals filed an Abbreviated New Drug Application (ANDA) in 2007, and Wyeth and Nycomed sued Teva for patent infringement, but Teva decided to launch its generic drug "at risk" that year, before the patent had been invalidated. Wyeth launched an authorized generic in 2008. Pfizer and Takedas patent exclusivity expired in 2010, and an administrative exclusivity they had for pediatric use expired in January 2011, and full generic competition began. The litigation between Teva and Pfizer/Takeda was settled in 2013, with Teva paying the patent holders $2.15 billion in damages for its early launch. Society and culture
As of 2017, the drug was marketed under many brands worldwide, including as a combination drug with domperidone, a combination with itopride, in combination with both clarithromycin and amoxicillin, in combination with  levosulpiride, and in combination with naproxen. Other animals
Pantoprazole has been demonstrated to increase the 3rd compartment pH in alpacas. It has been shown to be generally safe to use in cattle, sheep and goats. See also
Hyoscine butylbromide
Pirenzepine

References
External links
"Pantoprazole". Drug Information Portal. U.S. National Library of Medicine.
Intal may refer to:

Intal, a brand name for the pharmaceutical drug cromoglicic acid
Intal language, an international auxiliary language
JC Intal, a Filipino professional basketball player